Clovis Oncology (NASDAQ:CLVS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Clovis Oncology (NASDAQ:CLVS) in a research report released on Wednesday, July 3rd, Stock Target Advisor reports. “Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, …

Read More »

How England is moving away from its British moorings

A small piece of social history was enacted in the wings last week as the “Ottoman grandson”, to cite Turkish newspapers, held centre stage in London with his one-point government. Both events illustrated the extent to which England is moving away from its English moorings. In one, a hallowed 19th-century …

Read More »